2020 ASCO Update: Zanubrutinib vs. Ibrutinib - Are Newer Generation BTK Inhibitors Better for Waldenstrom’s Macroglobulinemia? Can Venetoclax Be Added to DA-R-EPOCH in DLBCL and Richter’s?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2020 ASCO Update: Zanubrutinib vs. Ibrutinib - Are Newer Generation BTK Inhibitors Better for Waldenstrom’s Macroglobulinemia? Can Venetoclax Be Added to DA-R-EPOCH in DLBCL and Richter’s?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Neha Mehta-Shah

17 views

July 22, 2020

0 Comments

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Treatment-Related Quality of Life in MF

Feat. A. Hunter

New Treatment Strategies in DLBCL

Feat. L. Sehn

16:03

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin

15:26

Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan

35:28

UNC Lineberger Comprehensive Cancer Center

DLBCL Management: Updates for 2023

Feat. N. Grover

17:11

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Incorporating Novel Agents in Frontline DLBCL

Feat. L. Sehn

16:39

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Targeted Therapy Updates for Aggressive B-Cell Lymphomas

Feat. D. Landsburg

13:46

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Smart Stop Trial - Lenalidomide, Tafasitama…

Feat. J. Westin

33:48

SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: B-Cell Lymphoma

Feat. L. Nastoupil

21:58

MedNews Week

The Evolving 1L DLBCL Landscape: POLARIX, Novel Agents and Future Di…

Feat. M. Matasar

09:32

SOHO 2023 Eleventh Annual Meeting

Upfront Management of DLBCL

Feat. C. Flowers

20:58

SOHO Brazil 2023

2023 SOHO® Brazil: "Why Should I Worry About the Complexity of …

Feat. J. Abramson

09:27

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Ph2 EpiRCHOP Study - Tazemetostat With R-CH…

Feat. C. Sarkozy

18:10

SOHO Turkey 2023

SOHO Turkey 2023: DLBCL Management

Feat. I. Barista

20:55

UChicago Medicine

Back to the Shop: What Happens When the CAR Fails in Lymphoma

Feat. A. Fadel

40:35

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Crossing Borders: Cell and Gene Therapy Outside the Boundaries

Feat. S. Mukherjee

17:41

5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Manage DLBCL

Feat. G. Musuraca

24:57

MedNews Week

Current Management of Newly Diagnosed DLBCL

Feat. M. Matasar

14:52

UChicago Medicine

42 y/o Male With Primary Refractory DLBCL: Case Discussion

Feat. A. Rojek

48:34

PleXus Communications

Emerging Cellular and Targeted Therapy Options for the Management of…

Feat. C. Jacobson

15:29

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Current Standards of Care for Aggressive Lymphomas

Feat. U. Vitolo

Login

Login

Join VuMedi

2020 ASCO Update: Zanubrutinib vs. Ibrutinib - Are Newer Generation BTK Inhibitors Better for Waldenstrom’s Macroglobulinemia? Can Venetoclax Be Added to DA-R-EPOCH in DLBCL and Richter’s?

Related Content